Rosen Law Firm Encourages Zeta Global Holdings Corp. Investors to Inquire About Securities Class Action Investigation - ZETA
Daily Post Nigeria Aviation regulatory agencies visit Ogun, certify Gateway Airport for commercial operations Home News Politics Metro Entertainment Sport News Aviation regulatory agencies visit Ogun, certify Gateway Airport for commercial operations Published on December 12, 2024 By Daily Post Staff A cross-section of regulatory agencies in the aviation industry visited the Gateway International Agro-Cargo Airport located along the Ilisan-Iperu axis of Ogun State on Tuesday, commending the quality of facilities put in place as well as its level of completion and thereby certifying it for commercial operations. The agencies, which comprised the Nigerian Civil Aviation Authority (NCAA), Nigerian Airspace Management Agency (NAMA), and Nigerian Meteorological Agency (NiMet), unanimously adjudged the airport as world-standard and a source of pride for Ogun State. According to the agencies, the critical infrastructure at the airport, which includes the Control Tower, Weather Monitoring Areas, Runway, Fire Service Stations, and the Apron, can rival any of its type around the world and remain one of the best in the West African corridor. Speaking during the visit, the Director of Aerodrome and Airspace Standards of NCAA, represented by Ango Mohammed, noted a significant improvement in the state of the facilities at the airport since his last visit, which is now at the level of any other towers in every standard airport around the globe. Mohammed said the quality of work carried out at the airport by the Ogun State Government should elicit accolades from all, and he expressed the delight of the Nigerian Civil Aviation Authority over the project. Also speaking, the representative of the Managing Director of NAMA, Tayo John, noted that the purpose of their visit to the airport was to inspect the facilities on-site to ascertain whether they are in strict compliance with the requirements for the provision of air traffic services and safety. Meanwhile, the Senior Project Manager of Craneburg, the construction company handling the project, Nicolas Mfarrej, said the airport is about 98% ready to take off fully and begin to serve the interests of the state. In the same vein, the Consultant on regulatory matters to the Ogun State Governor, Engineer Oluwole Adeyileka, explained that the key players in the regulation and monitoring of facilities for full airport operations had come to assess the level of readiness of the state, adding that it was noteworthy that they had been impressed by what the state had put in place at the airport. In their separate remarks, the Manager of Gateway International Airport, Captain Dapo Olumide, and the Commissioner for Works and Infrastructure, Engineer Ade Akinsanya, said the ongoing assessment is the last hurdle to be crossed before the airport could go on full commercial operations, adding that the assessment given had shown that the state is set to take the lead in air traffic services in the country, describing it as a good outcome of great commitment and dedication to the realization of the dream of an airport that can meet world standards. Related Topics: Gateway Airport ogun Don't Miss BSUTH to partner with pharmaceutical companies for sustainable drug supplies You may like Many journalists in Ogun hypertensive but not aware – Medical expert Ogun gets new Commissioner of Police Ogun govt distributes relief items to flood, fire victims Ogun govt rewards outstanding athletes at National Youth Games Ogun Govt to establish cocoa enclave in 3 senatorial districts Abiodun woos JBS, says Ogun ready to partner Brazilian livestock giant Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd
The Canadian economy grew 0.3 per cent in October, helped by strength in oil and gas extraction, mining and quarrying, Statistics Canada has revealed in its monthly GDP release. Oil and gas extraction, mining and quarrying rose 2.4 per cent in October with all three subsectors rising. " " wrote Andrew DiCapua, a senior economist at the Canadian Chamber of Commerce, in a note to clients. " ," he added. The threats of tariffs under a second Trump administration have not dissuaded Canadian oil and gas majors from drawing up plans to drill even more. Canada’s oil sands producer, (NYSE:SU), has unveiled plans to increase its oil and gas output next year as it continues to work to improve its performance and lower costs from its assets. Suncor has to grow oil and gas production to between 810,000 and 840,000 barrels per day in 2025, up from its 2024 estimated range of 770,000 to 810,000 barrels per day, and sees annual refining utilization of 93% to 97%. In terms of capex, the oil sands giant plans to spend in the range of C$6.1 to C$6.3 billion, with 45% allocated to economic investments. That marks a reduction from C$6.3 billion to C$6.5 billion for 2024 capex. Suncor's lower cash operating costs per barrel reflects its initiative to reduce its corporate WTI breakeven by $10 per bbl versus 2023, the company said. Canada’s (NYSE:IMO) and (NYSE:CVE) have unveiled similar plans, even as Canadian oil and gas stocks continue to outperform their American brethren. Canada’s the , has returned 17.6% in the year-to-date, more than 4x the 4.3% gain by the .
Some directors are good with music. James Mangold is one of them. Back in 2006, “Walk the Line” scored five Oscar nods and won Best Actress for Reese Witherspoon as June Carter Cash. (Joaquin as Johnny Cash lost to Philip Seymour Hoffman in “Capote”). A hard-drinking Johnny Cash (Boyd Holbrook) makes a memorable appearance in “ A Complete Unknown ” (in theaters December 25 from Searchlight), Mangold’s latest music movie, this time focused on the four-year origin myth of Bob Dylan, from his arrival in New York at age 19 in 1961 to his going electric at the Newport Folk Festival in 1965. Mangold is returning to his bent for more personal filmmaking (Best Picture Oscar nominee “Ford v Ferrari” ) after tackling 2023 franchise entry “Indiana Jones and the Dial of Destiny” for Steven Spielberg. The writer/director spoke to me on Zoom during his global press tour for “A Complete Unknown,” which has earned upbeat reviews, especially for Timothée Chalamet . On the awards circuit, Chalamet could follow his Best Actor Oscar nomination for “Call Me By Your Name” with a second, while Mangold and Jay Cocks are in the running for Adapted Screenplay; Mangold was nominated for Adapted Screenplay for “Logan” but has never made it into the Best Director circle. So far “A Complete Unknown” is landing with awards groups, nabbing the same three Golden Globe and Critics Choice Award nominations for Chalamet, supporting actor Edward Norton, and Best Motion Picture Drama/Picture; Elle Fanning won Best Supporting Actress from the National Board of Review, and the film made it to both the NBR and AFI Top Ten. This Zoom interview has been edited and condensed for clarity and brevity. Anne Thompson: Did you hear Zane Lowe’s unfettered interview with Timothée? James Mangold: It was remarkable. I love him. He’s a remarkable young man. Our journey on this movie has been five-and-a-half years. We met for the first time in 2019 at the Toronto Film Festival. I had just gotten my hands on the Elijah Wald book and Jay Cocks’ script. And there was a project in turnaround from HBO, and I had heard Timmy was interested in it. That was a home run idea. I had only a week ago just heard about the material, found out Timmy was in Toronto while I was there. So on the day that “Ford v Ferrari” premiered, I met with him there and told him how I saw the movie working in the most abstract sense. Do you remember that pitch? The simplest version was using “Amadeus” as a template. The way to structure this was to use the supporting cast to see the effect that genius has on them and to try to understand Bob through each of their eyes, instead of trying to crack him in the classic Freudian sense that he would have some big scene in the third act where he confesses some secret that everyone’s been waiting for, which from all my research, I’m not sure there is one. [Timmy] was excited, and he was thrilled. The fact that I made “Walk the Line” gave him confidence. He’s also a quick decision-maker and an instinctual actor. We decided to do this together, and I went to work revising the script. How big a Dylan fan were you at that point? The project didn’t come from me being a Dylan fan. I’ve listened to Dylan all my life, and like many people have gone in and out... listening to him non-stop, and then I have to take a rest, and then a year later, another wave of Dylan comes into my life. I wasn’t walking around going: “I’ve got to make a Bob Dylan movie.” The idea of making a movie about any true-life person, alive or dead, is to know what part of their life you’re making a movie about [before] you start to assemble a birth-to-retirement or death storyline that is so sprawling that it rarely has thematic unity to it at all. The book Cocks had adapted was focused on the road to the electric breakout? Jay wrote many scenes that still survive in the movie now. But Jay went into 1965 quickly. And I wanted to watch this ascent, and there wasn’t any folk period in the early 1960s. He did introduce Woody [Guthrie, played by Scoot McNairy], but then you jumped forward. The idea of keeping Woody alive through the movie for visits mid-picture and at the end of the movie was another thing I felt was important, to keep him, literally and figuratively, alive through the movie as a primal touchstone for Bob. Was Pete Seeger [Edward Norton] supposed to be what Dylan became? He was going to take over the folk mantle and be the popularizer of folk music, and he handed it to Dylan? Do you see it that way? Not exactly. I deeply admire Pete Seeger. I learned to play banjo in high school, inspired mainly by Pete and Steve Martin, but it’s not controversial to say that Pete only wrote a handful of songs and was much more of a missionary and an evangelist for folk music. Then he was an iconic artist whose unique brand of folk music defined and lifted all folk music. His optimism and generosity and sense of lifting all other boats, as he did with Bob and Joan and many others, and his sense of causes, which he would attach himself to all the way to the end of his life with Toshi, his wife, saving the Hudson River, were who Pete was. Look at it this way: Woody Guthrie, singer-songwriter, auteur, prickly, difficult man, salt of the earth; Pete Seeger, more of an evangelist operator, expert communicator, who was lifting Woody’s work and all the others. And then into their world arrives this star that Pete Seeger recognizes, who has some of what Pete doesn’t have, youth and edge, and a songbook that is staggering, and Seeger recognizes the value of an artist like this and immediately embraces him and is rewarded with Dylan becoming the center, holding up the circus tent of folk music. Did Dylan eventually betray Seeger? Did Bob ever agree to anything? Did he take a pledge? I don’t think he’s betrayed. Must all marriages, even ones that are unofficiated, last forever? And these are the questions the movie asks. In our movie, in the first scene alone with Pete in a car, Bob is clear that he’s not necessarily drinking the same kind of purity; he doesn’t view things in the same clearly divided way. You know that he doesn’t see things as us vs. them. He admires Little Richard and Hank Williams and Johnny Cash, and these are all influences which he thinks are marvelous, and they play on the pop charts, and they have drums and keyboards and rhythm sections. Bob becomes what Pete suggests and excels at it as a solo artist. You spoke with Dylan. Dylan himself was clear to me that he never envisioned himself being a solitary artist on stage. That was not his kind of dream. So that’s why he came to pay homage to Woody, who also, by the way, played with many string bands and bands in his career. But that didn’t mean that all he wanted was to be the Bob Dylan that he became. Dylan’s break toward electric music or band music was something that he always wanted to do and it was actually a matter of how long he was going to hold himself back to maintain this kind of tribalism that had divided these two camps from each other. Also Johnny Cash played at Newport Folk Festival many times, and had no problem as they brought a complete band on the stage. So obviously their concern about Dylan was that he was a symbol of their music. Johnny was a country music star coming as a special guest, a novelty, but Bob was folk, and if Bob turned to something other than folk, the tent might collapse. It struck Timothée that who Dylan was and what he represents is the exact opposite of what everything is today. The movie shows us not that he was pure but that he was true to his art. I agree with Timothée’s observation. [Bob] wanted to paint, but he didn’t want to be the voice in your headphones at MoMA, when you look at the paintings, he didn’t want to have to explain his work. And I think we’ve only gotten worse in that we can’t look at mystery. Art is mystery. The power of art is that it could be read different ways by different people. That it is not journalism. And it is not a Wikipedia entry, and it is not a set of facts or bullet points or simple references, and that to point out what you’re doing is to cheapen your work, and that those of us like Timothée and myself who live in this modern era, we know that’s unavoidable. You have to do it. But Dylan avoided it. But I don’t think it was out of intellectual fortitude or artistic ethics. Dylan was uncomfortable with interviews and with explication of oneself and one’s intentions. It’s easy for one to take what could be the result of a social anxiety and make it an artistic dogmatic position. And I tried to write the script with Jay that tried to depict [Dylan] as someone who loved making, but he didn’t necessarily enjoy or find comfort or even could be unwound by this mass adoration. His goal was never gigantic adoration. His goal was always to send these missives out in the world and let people process them. Timothée had to find that balance where he’s hooded, enigmatic, and mysterious but is also trying to draw you in while he’s keeping you out. It’s hard to pull off. Yes, but I don’t think Timmy tried to keep us out. I don’t think that’s a way you can direct an actor. One of the most beautiful touches early in the film that Timothée did in one take that I circled immediately, was Elle Fanning and him are out on a date, and they’re walking by a subway station, and she writes her number on his hand, and then she kisses his cheek, and Timmy has this moment where he flinches as she kisses his cheek, almost like it scares him a little. It was a penetrating moment: What if this character is actually living with an element of fear and anxiety about social interaction and love and connection, that it’s scary for them? I had this theory that the best angle would be to play him so that the outside world and the sensory world is intrusive to him, and it’s a struggle for him to stay present, and that instead of assuming everything is an attitude or an edge, what if there’s social awkwardness and a lack of filter that makes him blurt out things that are resoundingly blunt to the point that they seem impolite? But where he exists is a space of extreme honesty that doesn’t work in our world; it comes off as rudeness. I tried to find other ways to look at his behavior and encourage Timothée to examine them. For instance, we can call his making stories up about his past a lie, but we can also call it a wish, meaning that he wished he wasn’t a middle-class kid who grew up in comfort, the son of a man who owned a hardware store in Hibbing, Minnesota. He wished he came from the carnival and the rails and the dirt of the alleys like Woody Guthrie. And so those wishes becoming fantasies became legend, and I was trying to understand everything without assuming that he was this puppet master organizing this PR campaign of mystery and subterfuge, which I found slightly hard to believe. His sexual and professional bond with Joan Baez [Monica Barbaro], who was a bigger star, goes on through the movie until he turns up in her hotel room playing guitar in the middle of the night and she kicks him out! Joan was the one equal. Yes, they had different talents. Joan had a nightingale’s voice. She was a masterful guitar player. She had a perfection in her execution of her songs, but she only wrote a handful of songs. On the other side you had Bob, who was more of a wild card, who didn’t always sing, even on pitch, he was sloppy and slightly provocative and rambling in his stage presence. And so they’re completely opposite, but completely fascinating to one another, because, of course, the songs are springing from him like a fountain and how annoying that might be for Joan, that somehow this disheveled and semi-rude, rumpled genius, had no problem springing forth. With songs that she wanted to sing. They loved each other and were fascinated by one another. But it was unavoidable that there would be a slight competitive nature between them, and that each would covet something that the other had. Bob coveted her beautiful voice, her beautiful visage, her brilliant execution, and admired her stardom and her professionalism. And Joan admired the artistic volcano out of which these songs seem to spring. You’ve said the movie isn’t political, but weren’t Dylan’s songs political in their time? All movies are political, either directly or metaphorically. “Ford v Ferrari” is political. I wanted to represent all sides. But does it involve politics? Yes, not even just the obvious politics of the moment, but also the politics of what is music here for? Now, music is almost entirely about the self. We have very little music about our world, we sing entirely about our personal lives. In preparing the music, you did pre-recordings, but once you were shooting, it became apparent that after years of pandemic and strike delays with time for practice, the live performances were better? Was that scary ? It was less scary for me than it was for my sound team and in the edit room. Recordings are more challenging in these different locations, wherein to get a quality recording of the guitar playing, banjo playing, and singing, you have trucks going by, random creaks and sounds. And I had to convince them I didn’t care, that we could fix them later. But there were myriad technical issues, like, “What if Timmy plays the song at one rhythm in one take and then increases by two rhythm beats the next take?” The truth was, he did; the rhythm does vary slightly, but you don’t feel it because the song is so alive. It was much ado about nothing compared to the gains we got by allowing him to do it. It was a process that was rolling. I let us do the first song live; that worked so well we tried it again with the next. And in a sense, we always held the pre-records back there as a backup, and as we rolled forward, we got better and better. The sound team figured out where to hide mics in [Chalamet’s] hair or his hat, or secret mics inside the guitar. Everyone adapted and suddenly developed a brilliant technique to make it all happen. And you somehow got the period right. I grew up in New York in the ’60s and ’70s. I was born in ’63 but I remember those streets, the smell of them, the pickle barrels, the wonderful collection of humanity. That later period, 1969, is harder because you could look like a road production of “Hair” if you don’t watch yourself. But this period, as Bob himself said, the early ’60s were an extension of the ’50s, and the late ’60s were the beginning of the ’70s. And the ’60s, according to Bob, didn’t really exist. There was a dividing line at ’65 and everything onward was a prologue to the ’70s. The big change occurred somewhere around the Newport concert, and the arrival of the Beatles and The Stones, and the worsening of the Vietnam War, and the assassinations, and Woodstock, became demarcations of of a dramatic cultural shift. You recreated Greenwich Village in New Jersey? One of the advantages we had by landing in New Jersey: for a lot of the street scenes, we found blocks that were still pretty much exactly as they were 60 years ago, and they just required a bit of dressing. If you tried to shoot this in New York, there’s not a single block we could even afford to shut down, given the five-star restaurants and businesses that would never agree to anything that didn’t give them each $100,000 a night to close. We shot a few days in New York, obviously, outside the Chelsea Hotel and the Supreme Court courthouse. But most of it was in New Jersey. This is not a conventional narrative. How did you keep the audience invested in the story, even though it was basically a string of musical performances? First of all, I viewed the musical performance as part of the scenes. I viewed the songs as part of the scene where the actors were acting, but on pitch. I had the same demands when they were singing as when they were acting without singing, which is that there always had to be a subtext. There always had to be dramatic tension, whether in the wings or between each other on the stage or with someone in the audience, that I never wanted it to just be wholly a recreation of a famous concert. Watching people sing is no different than when you’re doing an action sequence in an action picture: if there isn’t story development inside the action, or if there isn’t story development inside the song, then the song is a commercial break from the drama of the movie, and the movie unwinds. In the film, Chalamet performs 40 songs, some are guitar or harmonica or radio fragments, including 26 whole songs. He prepared 30 songs, but you had to pick the ones that you put in the movie for a reason. When I started writing, I was just dropping the songs where they went in. I was conscious of how the songs gained power as explications of his emotional state in the context of what was going on politically and emotionally for him at that time. So him singing “Song for Woody” couldn’t be more intentional. Each one of these songs were revealing another aspect of him, also a different energy. Many of his songs were talking directly to the audience. Had that been done much before? Folk music, at that point, existed as a world of covers. All popular music was primarily in [the early ’60s] people singing standards, even Coltrane and Davis, most of their albums were taking Rodgers and Hammerstein tunes, or “My Funny Valentine,” or taking popular melodies and bending them. What happened in the age of Dylan? The power of modern songwriting. Personal songwriting took over, and this idea that we only should sing songs that existed already, that have proven themselves with time, evaporated. And that’s what opened the door for Dylan’s descendants, because he was ready with a portfolio of insanely powerful original music. This film is an antidote to what is going on in Hollywood. It is the opposite of franchise filmmaking, and while we know Dylan and his songs, this is a modest movie that celebrates a gritty authenticity that we don’t see much anymore. I move between those worlds, and in some ways, they give me the license to drive and make these movies, and the wherewithal to put them together financially. And otherwise, these are a big risk for studios, especially if they’re going out theatrically. It’s a white elephant at this point that you have mainstream studios making original movies that don’t have a guaranteed audience, that rely upon execution in order to succeed. And I’m grateful to Searchlight and my friends at Disney for supporting me on this movie because it is a risk, and I miss these movies in the theater. And I grew up on 7’0s films, and so my style is, if anything’ more formed from the work of Mike Nichols and Alan Pakula and Steven Spielberg and Martin Scorsese and Sidney Lumet and William Friedkin and Bogdanovich, these are the movies I grew up on. And these were all extremely versatile filmmakers who moved from comedy to serious to fantasy to adventure, and there wasn’t this demand that we exist in a lane or a box. I feel that the work I do, moving from one to the other, is always additive, that I learned something about making a horror film that I bring to a musical biopic. I learned something making a fantasy film or a Marvel film that then becomes confidence in how to solve a problem in a dramatic scene. Making a movie like this, finding a bunch of amazing, committed, passionate young actors who are all supporting each other, lifting each other, the environment and the camaraderie on the set was a real joy and we felt purpose, because we felt that this music was about a world in which art could change things, not by directly protesting, but by getting under your skin, by reminding you that we can look within and ask ourselves some of these questions about the direction our world is heading without hitting us over the head with a history lesson or shaming us, so that we could be inspired to think about what our world could be. “A Complete Unknown” will be released in theaters December 25.
FiscalNote Announces Update to Board of Directors
Trend Micro Achieves 100% Coverage Rate In MITRE ATT&CK® Evaluations Media Outreach Newswire APAC
Consumer IAM Market: $12.85B in 2022, Forecast to Reach $31.05B by 2031 12-05-2024 09:18 PM CET | IT, New Media & Software Press release from: SkyQuest Technology Consumer IAM Market Scope: Key Insights : Consumer IAM Market size was valued at USD 12.85 billion in 2022 and is poised to grow from USD 14.17 billion in 2023 to USD 31.05 billion by 2031, growing at a CAGR of 10.3% in the forecast period (2024-2031). Discover Your Competitive Edge with a Free Sample Report : https://www.skyquestt.com/sample-request/consumer-iam-market Access the full 2024 Market report for a comprehensive understanding @ https://www.skyquestt.com/report/consumer-iam-market In-Depth Exploration of the global Consumer IAM Market: This report offers a thorough exploration of the global Consumer IAM market, presenting a wealth of data that has been meticulously researched and analyzed. It identifies and examines the crucial market drivers, including pricing strategies, competitive landscapes, market dynamics, and regional growth trends. By outlining how these factors impact overall market performance, the report provides invaluable insights for stakeholders looking to navigate this complex terrain. Additionally, it features comprehensive profiles of leading market players, detailing essential metrics such as production capabilities, revenue streams, market value, volume, market share, and anticipated growth rates. This report serves as a vital resource for businesses seeking to make informed decisions in a rapidly evolving market. Trends and Insights Leading to Growth Opportunities The best insights for investment decisions stem from understanding major market trends, which simplify the decision-making process for potential investors. The research strives to discover multiple growth opportunities that readers can evaluate and potentially capitalize on, armed with all relevant data. Through a comprehensive assessment of important growth factors, including pricing, production, profit margins, and the value chain, market growth can be more accurately forecast for the upcoming years. Top Firms Evaluated in the Global Consumer IAM Market Research Report: IBM Corporation Microsoft Corporation Okta, Inc. Salesforce.com, Inc. Transmit Security Akamai Technologies, Inc. SAP SE Ubisecure LoginRadius Key Aspects of the Report: Market Summary: The report includes an overview of products/services, emphasizing the global Consumer IAM market's overall size. It provides a summary of the segmentation analysis, focusing on product/service types, applications, and regional categories, along with revenue and sales forecasts. Competitive Analysis: This segment presents information on market trends and conditions, analyzing various manufacturers. It includes data regarding average prices, as well as revenue and sales distributions for individual players in the market. Business Profiles: This chapter provides a thorough examination of the financial and strategic data for leading players in the global Consumer IAM market, covering product/service descriptions, portfolios, geographic reach, and revenue divisions. Sales Analysis by Region: This section provides data on market performance, detailing revenue, sales, and market share across regions. It also includes projections for sales growth rates and pricing strategies for each regional market, such as: North America: United States, Canada, and Mexico Europe: Germany, France, UK, Russia, and Italy Asia-Pacific: China, Japan, Korea, India, and Southeast Asia South America: Brazil, Argentina, Colombia, etc. Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, and South Africa This in-depth research study has the capability to tackle a range of significant questions that are pivotal for understanding the market dynamics, and it specifically aims to answer the following key inquiries: How big could the global Consumer IAM market become by the end of the forecast period? Let's explore the exciting possibilities! Will the current market leader in the global Consumer IAM segment continue to hold its ground, or is change on the horizon? Which regions are poised to experience the most explosive growth in the Consumer IAM market? Discover where the future opportunities lie! Is there a particular player that stands out as the dominant force in the global Consumer IAM market? Let's find out who's leading the charge! What are the key factors driving growth and the challenges holding back the global Consumer IAM market? Join us as we uncover the forces at play! To establish the important thing traits, Ask Our Experts @ https://www.skyquestt.com/speak-with-analyst/consumer-iam-market Table of Contents Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.5 Market Size Analysis from 2023 to 2030 11.6 COVID-19 Outbreak: Medical Computer Cart Industry Impact Chapter 2 Competition by Types, Applications, and Top Regions and Countries 2.1 Market (Volume and Value) by Type 2.3 Market (Volume and Value) by Regions Chapter 3 Production Market Analysis 3.1 Worldwide Production Market Analysis 3.2 Regional Production Market Analysis Chapter 4 Medical Computer Cart Sales, Consumption, Export, Import by Regions (2023-2023) Chapter 5 North America Market Analysis Chapter 6 East Asia Market Analysis Chapter 7 Europe Market Analysis Chapter 8 South Asia Market Analysis Chapter 9 Southeast Asia Market Analysis Chapter 10 Middle East Market Analysis Chapter 11 Africa Market Analysis Chapter 12 Oceania Market Analysis Chapter 13 Latin America Market Analysis Chapter 14 Company Profiles and Key Figures in Medical Computer Cart Business Chapter 15 Market Forecast (2023-2030) Chapter 16 Conclusions Address: 1 Apache Way, Westford, Massachusetts 01886 Phone: USA (+1) 351-333-4748 Email: sales@skyquestt.com About Us: SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally. This release was published on openPR.
Intel ( INTC 3.28% ) stock is climbing in Thursday's trading. The semiconductor company's share price was up 3.1% as of 3:15 p.m. ET. Meanwhile, the S&P 500 index and the Nasdaq Composite index were both down 0.5%. Intel stock is gaining ground today following a presentation from co-CEOs Michelle Johnston Holthaus and David Zinsner at Barclay's Global Technology Conference . The executives shared some insight into the direction of the business going forward, and Wall Street seems to have been somewhat comforted by the content of the presentation. Intel stock is down roughly 59% in 2024. Intel starts to make its plans a bit more clear Holthaus and Zinsner stepped in as co-CEOs following the recent departure of former-CEO Pat Gelsinger. The company's path forward amid underperformance for its chip design and semiconductor fabrication units was already a concern for investors, and Gelsinger's resignation only added to the uncertainty surrounding the business. With today's presentation at the Barclarys conference, Holthaus and Zinsner shared some new insights and commented on Intel's direction going forward. Most notably, they said that Intel's foundry business is in the process of being shifted to be a subsidiary. This means it will operate pretty much entirely separately from the chip-design division. The executives also left the door open for the foundry business to be spun off entirely, but Zinsner said that whether the unit would ever be fully separated was a question for another day. What's next for Intel? Intel is going through some dramatic structural changes. In addition to discussing plans for creating more separation for the foundry business, Holthaus and Zinsner indicated that the company was open to selling some of its stake in machine-vision specialist Mobileye . It's also looking for a partner to help take its Altera unit public again. Intel acquired the programmable chips specialist for $16.7 billion in 2015. As mentioned in the Barclays presentation, Intel has also been facing significant competitive pressures in the chip design space -- and Holthaus highlighted recent wins by Advanced Micro Devices as something the company needs to do a better job of combatting. Along those lines, Intel is aiming to make 2025 a year of stabilization and regaining market share in the data center, and the company acknowledges it has a lot of work to do when it comes to taking advantage of artificial intelligence ( AI ) opportunities.17 Analysts Assess Monday.Com: What You Need To Know
I’ve worn then returned 100 glitzy party dresses as a serial ‘wardrober’ – I get a kick out of it & don’t spend a pennyKaroline Leavitt, the incoming White House press secretary, told Fox News on Thursday that Mr Trump wanted to create an “open dialogue” with countries that were American adversaries, not just with allies and partners. “We saw this in his first term. He got a lot of criticism for it, but it led to peace around this world. He is willing to talk to anyone, and he will always put America’s interests first,” said Ms Leavitt. Ms Leavitt said it was “to be determined” if Mr Xi would accept the invitation. The Chinese embassy did not immediately respond to a request for comment. The invitation comes as Beijing is bracing for an escalation in the trade war that Mr Trump launched against China in 2018. The US president-elect has already threatened to impose a 60 per cent tariff on imports from China, which would be a big increase from the levies he imposed on the country’s goods in his first term. Mr Trump will enter office as US-China relations remain close to their worst state since the countries established diplomatic relations in 1979. The US is concerned about Chinese military activity around Taiwan and coercive activity towards countries such as the Philippines in the Indo-Pacific. China in turn accuses the US of meddling in its internal affairs over Taiwan and is angry at US export controls that are designed to make it harder for the Chinese military to use American technology to modernise. [ ‘This is not easy for me’: FBI director resigns before Donald Trump takes office Opens in new window ] Mr Trump has also picked several extremely hawkish officials to serve in top national security roles. He has said he will nominate senator Marco Rubio, one of the most vocal China hawks in Congress, to be secretary of state, and intends to appoint Mike Waltz, a Florida congressman and former Green Beret, as his White House national security adviser. Mr Trump had a complicated relationship with China during his first term. He courted Mr Xi in 2017 before launching a trade war the following year. But he took a tough stance on economic and security issues in 2020 as he blamed Beijing for the Covid-19 pandemic, which emerged from Wuhan. Chinese officials have in recent months been desperately trying to determine what Mr Trump wants to achieve in his dealings with China, and whether he wants to push for some kind of a deal with Mr Xi, including on trade. Several people close to the Trump team said they expected that the president-elect would take tough approach on trade early in his administration to force China to come to the negotiating table. Bonnie Glaser, a China expert at the German Marshall Fund, said it was unlikely that Mr Xi would attend the inauguration. “Xi will likely send a representative, possibly vice-president Han Zheng,” said Ms Glaser. “He will come when all eyes are on him for a separate summit. Optics are extremely important for the Chinese.” – Copyright The Financial Times Limited 2024Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Chaos at Capitol as Marylanders retain Key Bridge funding pledge in new spending bill, source saysDiamcor and Tiffany & Co. Canada Sign Agreement to Amend Outstanding Loans
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi BioscienceColor Star Technology Regains Compliance with Nasdaq Minimum Closing Bid Price Rule